IconOVir is working to develop oncolytic virus therapy to treat cancer patients. Dr. Maltzman will be tasked with the development of the company’s oncolytic virus therapeutics platform, according to the Oct. 10 IconOVir news release.
Prior to her new position, Dr. Maltzman served as franchise head, vice president, and global head of gastrointestinal and cancer immunotherapy at Genentech.
“We are thrilled to welcome Julie to our team as we prepare to advance ICVB-1042, our lead product candidate, into first-in-human Phase 1 studies next year,” said Mark McCamish, MD, PhD, IconOVir CEO and president. “Julie is an accomplished leader in oncology drug development, and we believe that her extensive clinical experience, coupled with her background as a medical oncologist, will be instrumental in our efforts to unlock the full potential of ICVB-1042, while also supporting the growth of our broader OV-based therapeutic pipeline.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.